272 Stock Overview
Mabion S.A., a biotechnology company, engages in the development of various biotech drugs based on monoclonal antibody technology in Poland.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 5/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Mabion S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | zł3.74 |
| 52 Week High | zł5.57 |
| 52 Week Low | zł3.41 |
| Beta | 0.97 |
| 1 Month Change | 1.80% |
| 3 Month Change | -8.15% |
| 1 Year Change | -4.10% |
| 3 Year Change | -73.44% |
| 5 Year Change | n/a |
| Change since IPO | -72.38% |
Recent News & Updates
Recent updates
Shareholder Returns
| 272 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -5.6% | -0.2% | 0.5% |
| 1Y | -4.1% | -22.8% | 1.3% |
Return vs Industry: 272 exceeded the German Biotechs industry which returned -23% over the past year.
Return vs Market: 272 underperformed the German Market which returned 2.3% over the past year.
Price Volatility
| 272 volatility | |
|---|---|
| 272 Average Weekly Movement | 4.0% |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 272 has not had significant price volatility in the past 3 months.
Volatility Over Time: 272's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 244 | Krzysztof Kaczmarczyk | www.mabion.eu |
Mabion S.A., a biotechnology company, engages in the development of various biotech drugs based on monoclonal antibody technology in Poland. The company develops, produces, and sells medicines for the treatment of neoplastic, autoimmune, metabolic, and neurological diseases. Its products include MabionCD20 and MabionHER2.
Mabion S.A. Fundamentals Summary
| 272 fundamental statistics | |
|---|---|
| Market cap | €61.84m |
| Earnings (TTM) | €9.56m |
| Revenue (TTM) | €35.13m |
6.5x
P/E Ratio1.8x
P/S RatioIs 272 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 272 income statement (TTM) | |
|---|---|
| Revenue | zł151.68m |
| Cost of Revenue | zł37.10m |
| Gross Profit | zł114.58m |
| Other Expenses | zł73.31m |
| Earnings | zł41.27m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 15, 2024
| Earnings per share (EPS) | 2.55 |
| Gross Margin | 75.54% |
| Net Profit Margin | 27.21% |
| Debt/Equity Ratio | 26.8% |
How did 272 perform over the long term?
See historical performance and comparison